Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anticoagulation of valvular prostheses].

G Hanania1, J P Maroni, Y el Hajj

  • 1Service de cardiologie, hôpital Robert-Ballanger, 93602 Aulnay-sous-Bois, France. cardio@ch-aulnay.fr

Annales De Cardiologie Et D'Angeiologie
|January 13, 2004
PubMed
Summary

Mechanical heart valves require lifelong anticoagulation to prevent clots. Guidelines detail oral anticoagulants and heparin use, with intensity tailored to individual risk factors and prosthesis type. Monitoring and alternative therapies are crucial for managing risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The white book of the National College of Hospital Cardiologists (NCHC) -- to respond to a public health issue].

Annales de cardiologie et d'angeiologie·2012
Same author

[Operative risk of heart valve surgery after 80 years].

Annales de cardiologie et d'angeiologie·2006
Same author

Bypassing the emergency room reduces delays and mortality in ST elevation myocardial infarction: the USIC 2000 registry.

Heart (British Cardiac Society)·2006
Same author

High risk hypertensives: pre-hospital management of acute myocardial infarction--results from the French nationwide registry USIC 2000.

Annales de cardiologie et d'angeiologie·2006
Same author

[Management of patients admitted for acute myocardial infarction in France from 1995 to 2000: time to admission dependent improvement in outcome].

Archives des maladies du coeur et des vaisseaux·2005
Same author

Major impact of admission glycaemia on 30 day and one year mortality in non-diabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study.

Heart (British Cardiac Society)·2005

Area of Science:

  • Cardiology
  • Vascular Surgery
  • Pharmacology

Background:

  • Severe valvular heart disease necessitates prosthetic valve replacement, with mechanical prostheses requiring lifelong anticoagulation.
  • Established national and international guidelines provide frameworks for managing anticoagulant therapy in patients with mechanical heart valves.
  • Anticoagulant therapy is essential for reducing thromboembolic risk but carries an inherent risk of hemorrhage.

Purpose of the Study:

  • To review current guidelines and practices for anticoagulant therapy in patients with mechanical heart valves.
  • To discuss the factors influencing the intensity of anticoagulation and the role of monitoring.
  • To explore the use of heparin, low molecular weight heparins, and antiplatelet agents in specific clinical scenarios.

Main Methods:

Related Experiment Videos

  • Review of national and international guidelines on anticoagulation for prosthetic heart valves.
  • Discussion of therapeutic strategies based on prosthesis type, patient-specific risk factors, and clinical situations.
  • Analysis of the benefits and risks associated with oral anticoagulants, heparin, and antiplatelet agents.

Main Results:

  • Anticoagulation intensity is determined by prosthesis type, position, atrial fibrillation, and thromboembolic risk.
  • International Normalized Ratio (INR) is the standard for monitoring oral anticoagulant therapy.
  • Heparin therapy is crucial for managing high hemorrhage risk situations and during warfarin contraindications like pregnancy.

Conclusions:

  • Low molecular weight heparins are increasingly used off-label due to ease of use and stable action, supported by recent guidelines and publications.
  • Balancing the thromboembolic risk reduction with the hemorrhagic risk of anticoagulation is paramount.
  • Antiplatelet agents may be considered as an adjunct therapy in select patients, particularly those with atheromatous disease.